Loading
Depression / Major Depressive Disorder / MoodTriggers Application · Interventional Study
ClinicalTrials.gov · August 11, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a prospective interventional study registration evaluating whether continuous smartphone data can predict depression relapse in hospitalized or recently discharged patients. No results are yet posted in this registry record; the study is actively recruiting and designed to generate preliminary evidence on feasibility and predictive validity of a mobile monitoring application.
Interventional, Randomized, Parallel, Open label, Prevention purpose. Depression, Major Depressive Disorder; age from 18 Years. Intervention: Phase 1: Sensing System Calibration (N = 120). Compared with: Phase 2: Early warning system (n = 100) — Active Comparator; Phase 2: Usual Care (n = 100) — No Intervention. n = 320. 2 sites: United States.
This is a prospective interventional study registration evaluating whether continuous smartphone data can predict depression relapse in hospitalized or recently discharged patients. No results are yet posted in this registry record; the study is actively recruiting and designed to generate preliminary evidence on feasibility and predictive validity of a mobile monitoring application.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
If results demonstrate that smartphone-derived digital biomarkers can reliably predict depression relapse, this could enable earlier clinical intervention and reduce readmission rates; however, evidence is not yet available and clinical utility remains unproven.
This is an active registry record for an interventional study with no results posted; it describes a planned pilot evaluation of a smartphone monitoring application for depression relapse prediction in an estimated 320 participants.
As stated by the source record.
Quoted from the source exactly as published.
If results demonstrate that smartphone-derived digital biomarkers can reliably predict depression relapse, this could enable earlier clinical intervention and reduce readmission rates; however, evidence is not yet available and clinical utility remains unproven.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07174557). This is a study registration, not published results. Lead sponsor: Dartmouth-Hitchcock Medical Center. Recruitment status: RECRUITING. Phase: NA. Study type: INTERVENTIONAL. Enrollment: 320 participants (ESTIMATED). Conditions: Depression, Major Depressive Disorder. Interventions: OTHER: MoodTriggers Application. Primary outcome measures: Monthly depression relapse , discharge, 6-months post-discharge. Brief summary: Researchers hope to see if the data smartphones collect continuously can be used to predict if patient's depression symptoms will return. They will do this by collecting data from patient's smartphones and comparing it to their depression symptoms. If this method is successful, researchers could develop a smartphone application to help healthcare providers better monitor patient's depression and intervene earlier if symptoms return.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.